文献速递免疫规划传染病防控与疫情报告

评估志贺菌疫苗免疫原性的多重免疫分析方法的开发与确认

Development and qualification of a multiplexed immunoassay to assess the immunogenicity of Shigella vaccines.
PubMed 文献 · Vaccine · 2025-11-01

研究开发了基于Luminex的多重免疫分析方法,整合五种志贺菌血清型纯化脂多糖、IpaB蛋白及常见疫苗载体蛋白。该方法在全部抗原上确认了稀释线性(R²≥0.98),准确度与精密度符合预设标准,为多价志贺菌疫苗临床试验提供可扩展的免疫原性评估方案。

要点

  • 开发了覆盖五种志贺菌血清型脂多糖、IpaB蛋白及载体蛋白的Luminex多重免疫分析方法。
  • 全部抗原稀释线性R²≥0.98,准确度与精密度符合预设标准,定量范围最多跨两个数量级。
  • 该方法可准确高效测量疫苗诱导的多种志贺菌抗原抗体反应,适用于资源有限地区的临床试验。

核心结论

  • 该多重免疫分析方法能够准确、高效地测量针对多种志贺菌抗原和载体蛋白的疫苗诱导抗体反应,为多价志贺菌疫苗的临床试验提供经过确认的可扩展解决方案,尤其适用于资源有限的环境。

研究设计与样本

  • 开发了基于Luminex的多重免疫分析方法,整合五种志贺菌血清型(宋内志贺菌、福氏志贺菌1b、2a、3a和6型)的纯化脂多糖、志贺菌IpaB蛋白及常见疫苗载体蛋白。
  • 使用合并的疫苗接种后血清样本评估方法性能,确认参数包括线性、准确度、精密度和特异性。

主要发现

  • 全部抗原在宽动态范围内确认稀释线性(R²≥0.98),斜率范围为0.91至1.16。
  • 全部抗原的批内和批间准确度以及批内和批间精密度均符合预设标准,变异主要在高稀释度下见于福氏志贺菌1b和3a。
  • 每种抗原的定量下限与定量上限跨度最多达两个数量级。
  • 该多重方法对同源抗原表现出特异性,部分交叉反应模式反映了脂多糖血清型之间已知的结构相似性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Shigella is a major cause of diarrheal disease in young children worldwide, particularly in low- and middle-income countries (LMICs). The emergence of antibiotic resistance and limited access to healthcare in LMICs underscores the urgent need for an effective Shigella vaccine. Several next-generation Shigella vaccines are under development, many of which target the O-antigen component of lipopolysaccharide (LPS) from multiple serotypes to achieve broad protective coverage. Reliable, multiplexed assays are needed to evaluate vaccine immunogenicity across Shigella serotypes and vaccine platforms. METHODS: A Luminex-based multiplex immunoassay was developed incorporating purified LPS from five Shigella serotypes (S. sonnei, S. flexneri 1b, 2a, 3a, and 6) along with Shigella IpaB protein and common vaccine carrier proteins. Assay performance was evaluated using pooled post-vaccination serum samples with qualification parameters including linearity, accuracy, precision, and specificity. RESULTS: Dilutional linearity was confirmed in all antigens across a broad dynamic range (R2 ≥ 0.98), with slopes ranging from 0.91 to 1.16. Within-run and between-run accuracy and intra-assay and inter-assay precision met predefined criteria for all antigens, with variability primarily observed at high dilutions for S. flexneri 1b and 3a. The assigned lower and upper limits of quantitation (LLOQ-ULOQ) spanned up to two orders of magnitude per antigen. The multiplex assay demonstrated specificity for homologous antigens, with some cross-reactivity patterns reflecting known structural similarities among LPS serotypes. CONCLUSION: This multiplex immunoassay enabled accurate and efficient measurement of vaccine-induced antibody responses across multiple Shigella antigens and carrier proteins. It therefore offers a qualified scalable solution for evaluating multivalent Shigella vaccines in clinical trials, particularly in resource-limited settings.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Rhyne PW, Sunshine J, Hogrefe W, et al. Development and qualification of a multiplexed immunoassay to assess the immunogenicity of Shigella vaccines. Vaccine. 2025. PMID: 41176970. doi:10.1016/j.vaccine.2025.127896

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。